These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 17391324

  • 21. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
    Tsuchiya N, Satoh S, Tada H, Li Z, Ohyama C, Sato K, Suzuki T, Habuchi T, Kato T.
    Transplantation; 2004 Oct 27; 78(8):1182-7. PubMed ID: 15502717
    [Abstract] [Full Text] [Related]

  • 22. Association Between Tacrolimus Pharmacokinetics and Cytochrome P450 3A5 and Multidrug Resistance Protein 1 Exon 21 Polymorphisms.
    Soda M, Fujitani M, Michiuchi R, Shibayama A, Kanamori K, Yoshikuni S, Ohno Y, Tsuchiya T, Suzuki A, Horie K, Deguchi T, Itoh Y, Kitaichi K.
    Transplant Proc; 2017 Oct 27; 49(6):1492-1498. PubMed ID: 28736028
    [Abstract] [Full Text] [Related]

  • 23. Polymorphisms of tumor necrosis factor-alpha, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus.
    Li D, Zhu JY, Gao J, Wang X, Lou YQ, Zhang GL.
    Clin Chim Acta; 2007 Aug 27; 383(1-2):133-9. PubMed ID: 17568575
    [Abstract] [Full Text] [Related]

  • 24. Conversion from Twice-Daily Prograf® to Once-Daily Advagraf® in Multi-ethnic Asian Adult Renal Transplant Recipients With or Without Concomitant Use of Diltiazem: Impact of CYP3A5 and MDR1 Genetic Polymorphisms on Tacrolimus Exposure.
    Yau WP, Loh CW, Vathsala A.
    Eur J Drug Metab Pharmacokinet; 2019 Aug 27; 44(4):481-492. PubMed ID: 30471066
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Influence of the MDR1 haplotype and CYP3A5 genotypes on cyclosporine blood level in Chinese renal transplant recipients.
    Chen B, Zhang W, Fang J, Jin Z, Li J, Yu Z, Cai W.
    Xenobiotica; 2009 Dec 27; 39(12):931-8. PubMed ID: 19925383
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation.
    Vannaprasaht S, Reungjui S, Supanya D, Sirivongs D, Pongskul C, Avihingsanon Y, Tassaneeyakul W.
    Clin Ther; 2013 Nov 27; 35(11):1762-9. PubMed ID: 24120259
    [Abstract] [Full Text] [Related]

  • 31. Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients.
    Kuypers DR, de Jonge H, Naesens M, Vanrenterghem Y.
    Pharmacogenet Genomics; 2008 Oct 27; 18(10):861-8. PubMed ID: 18704002
    [Abstract] [Full Text] [Related]

  • 32. Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients.
    Qiu XY, Jiao Z, Zhang M, Zhong LJ, Liang HQ, Ma CL, Zhang L, Zhong MK.
    Eur J Clin Pharmacol; 2008 Nov 27; 64(11):1069-84. PubMed ID: 18636247
    [Abstract] [Full Text] [Related]

  • 33. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids.
    Mourad M, Mourad G, Wallemacq P, Garrigue V, Van Bellingen C, Van Kerckhove V, De Meyer M, Malaise J, Eddour DC, Lison D, Squifflet JP, Haufroid V.
    Transplantation; 2005 Oct 15; 80(7):977-84. PubMed ID: 16249748
    [Abstract] [Full Text] [Related]

  • 34. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
    Zhang X, Liu ZH, Zheng JM, Chen ZH, Tang Z, Chen JS, Li LS.
    Clin Transplant; 2005 Oct 15; 19(5):638-43. PubMed ID: 16146556
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
    Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, van Gelder T.
    Clin Pharmacol Ther; 2003 Sep 15; 74(3):245-54. PubMed ID: 12966368
    [Abstract] [Full Text] [Related]

  • 37. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
    Tada H, Tsuchiya N, Satoh S, Kagaya H, Li Z, Sato K, Miura M, Suzuki T, Kato T, Habuchi T.
    Transplant Proc; 2005 May 15; 37(4):1730-2. PubMed ID: 15919447
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Association between tacrolimus concentration and genetic polymorphisms of CYP3A5 and ABCB1 during the early stage after liver transplant in an Iranian population.
    Rahsaz M, Azarpira N, Nikeghbalian S, Aghdaie MH, Geramizadeh B, Moini M, Banihashemi M, Darai M, Malekpour Z, Malekhosseini SA.
    Exp Clin Transplant; 2012 Feb 15; 10(1):24-9. PubMed ID: 22309416
    [Abstract] [Full Text] [Related]

  • 40. Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients.
    Miao LY, Huang CR, Hou JQ, Qian MY.
    Biopharm Drug Dispos; 2008 Jan 15; 29(1):1-5. PubMed ID: 17941052
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.